PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ijpharmHomeCurrent issueInstructionsSubmit article
 
Indian J Pharmacol. 2010 June; 42(3): 197–198.
PMCID: PMC2937328

Authors’ reply

Sir,

We thank Dr. Mahajan for his comments[1] on our paper.[2] Our reply to the queries are as follows:

  1. The study was planned to focus the beneficial effects of irbesartan in comparison to insulin and thus the relevance of the study remains clear.
  2. Suggestion at 2 is well-taken for future studies.
  3. We regret the typing error; please read group III for insulin and group IV for irbesartan.
  4. It is a printing error. The original Table ((11 and and2)2) submitted to the journal office are reproduced here.
    Table 1
    Effect of irbesartan (20 mg/kg/po) pretreatment on urinary protein excretion in STZ-induced diabetic rats (values are mean ± SEM; n = 10 in each group)
    Table 2
    Effect of irbesartan (20 mg/kg, po) pretreatment on creatinine clearance in STZ-induced diabetic rats (values are mean ± SEM; n = 10 in each group)

References

1. Mahajan Irbesartan in experimental diabetic nephropathy. Indian J Pharmacol. 2010;42:197. [PMC free article] [PubMed]
2. Vaishya R, Singh J, Lal H. Biochemical effects of irbesartan in experimental diabetic nephropathy. Indian J Pharmacol. 2009;41:252–4. [PMC free article] [PubMed]

Articles from Indian Journal of Pharmacology are provided here courtesy of Medknow Publications